Remotely Activated Protein-Producing Nanoparticles

Protein therapeutics have emerged as a significant role in treatment of a broad spectrum of diseases, including cancer, metabolic disorders and autoimmune diseases. The efficacy of protein therapeutics, however, is limited by their instability, immunogenicity and short half-life. In order to overcome these barriers, tremendous efforts have recently been made in developing controlled protein delivery systems. Stimuli-triggered release is an appealing and promising approach for protein delivery and has made protein delivery with both spatiotemporal- and dosage-controlled manners possible. This review surveys recent advances in controlled protein delivery of proteins or peptides using stimuli-responsive nanomaterials. Strategies utilizing both physiological and external stimuli are introduced and discussed.

show abstract

“…9) [104]. This lipid based vesicle was filled with amino acids, ribosomes, and plasmid caged with a photolabile protecting group.…”

Section: External Stimuli-triggered Deliverymentioning

confidence: 99%

Stimuli-responsive nanomaterials for therapeutic protein delivery

Lü

Sun

2014

Journal of Controlled Release

384

285

View full text Add to dashboard Cite

show abstract

“…The basis for the interest lies in their unique properties achieved at the nanoscale that can be accessed via remote stimuli. These properties could then be exploited to simultaneously activate secondary systems that are not remotely actuatable [440,535,536,[553][554][555][556][557][558][559][560][561]. Despite all the work already performed, Richard Feynman is still more than right: "There is still Plenty of Room at the Bottom".…”

Section: Perspectives: Multimodal Theranostic Npsmentioning

confidence: 99%

Functionalized nanomaterials: their use as contrast agents in bioimaging: mono- and multimodal approaches

Trequesser¹,

Seznec²,

Delville³

2016

Nano Online

View full text Add to dashboard Cite

The successful development of nanomaterials illustrates the considerable interest in the development of new molecular probes for medical diagnosis and imaging. Substantial progress was made in synthesis protocol and characterization of these materials whereas toxicological issues are sometimes incomplete. Nanoparticle-based contrast agents tend to become efficient tools for enhancing medical diagnostics and surgery for a wide range of 2 imaging modalities. Multimodal nanoparticles (NPs) are much more efficient than conventional molecular-scale contrast agents. They provide new abilities for in vivo detection and enhanced targeting efficiencies through longer circulation times, designed clearance pathways, and multiple binding capacities. Properly protected, they can safely be used for the fabrication of various functional systems with targeting properties, reduced toxicity and proper removal from the body. This review mainly describes the advances in the development of mono-to multimodal NPs and their in vitro and in vivo relevant biomedical applications ranging from imaging and tracking to cancer treatment. Besides specific applications for classical imaging, (MRI, PET, CT, US, PAI) are also mentioned less common imaging techniques such as terahertz molecular imaging (THMI) or ion beam analysis (IBA).Perspectives on multimodal theranostic NPs and their potential for clinical advances are also mentioned.

show abstract

“…However, in case biological processes can occur within these soft nanomaterials, as may be the case in products from synthetic biology that can also be nano-sized (e.g. nano-sized ''protein factories'' which involves packaging the molecular machinery for making proteins in to a membraned capsule; Schroeder et al, 2012), such conclusions should not be drawn too quickly. Another specification in which nano-specific risk may be limited can be nanomaterials that quickly dissolve in -physiologically or environmentally -relevant media and change into non-nanomaterials.…”

Section: Further Issues To Be Addressedmentioning

confidence: 99%